UroGen Pharma Ltd.

NASDAQ: URGN · Real-Time Price · USD
19.74
-0.34 (-1.69%)
At close: Aug 15, 2025, 3:59 PM
19.50
-1.22%
After-hours: Aug 15, 2025, 06:59 PM EDT

UroGen Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
90.4M 82.71M 64.36M 48.04M
Cost of Revenue
8.88M 9.36M 7.65M 5.16M
Gross Profit
81.52M 73.35M 56.7M 42.88M
Operating Income
-96.78M -65.54M -79.04M -92.29M
Interest Income
8.9M 2.64M 938K 365K
Pretax Income
-124.04M -98.32M -108.03M -109.37M
Net Income
-126.87M -102.24M -109.78M -110.82M
Selling & General & Admin
121.15M 93.27M 82.84M 87.53M
Research & Development
57.15M 45.61M 52.91M 47.64M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
178.3M 138.89M 135.74M 135.18M
Interest Expense
12.52M 14.71M 8.44M 17.44M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
187.18M 148.25M 143.4M 140.33M
Income Tax Expense
2.83M 3.92M 1.75M 1.45M
Shares Outstanding (Basic)
42.88M 28.83M 22.81M 22.35M
Shares Outstanding (Diluted)
42.88M 28.83M 22.81M 22.35M
EPS (Basic)
-2.96 -3.55 -4.79 -4.96
EPS (Diluted)
-2.96 -3.55 -4.79 -4.96
EBITDA
-110.33M -60.35M -76.21M -90.15M
EBIT
-88.11M -62.06M -78.03M -91.93M
Depreciation & Amortization
1.19M 1.71M 1.82M 1.77M